Ascendis Pharma A/S
Ascendis Pharma A/S's revenue rose 98.0% to €720 million in fiscal 2025. Its operating margin was −18.9%, up from −76.7% a year earlier. It paid out €17 million in dividends and buybacks. The diluted share count rose 4.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
What Ascendis Pharma A/S does
Ascendis Pharma is a Danish biopharmaceutical company. It develops medicines using its TransCon technology, which it designs to release a drug slowly in the body. Its focus is rare endocrine diseases, mainly hypoparathyroidism and growth disorders.
Its approved products include YORVIPATH, a treatment for hypoparathyroidism. YORVIPATH has been available by prescription in the United States since December 2024, in several European countries, and in Japan through its partner Teijin since November 2025. The company also sells a growth hormone treatment and has other candidates in development.
Ascendis has also set up partnerships to bring TransCon-based products to larger areas such as metabolic and cardiovascular disease and eye disease. It sells through its own sales teams and through partners.
Its biggest risks, as it describes them
- Losses in the past and possibly in the future, making its long-term viability hard to judge.
- Heavy reliance on its TransCon technology and a small number of products.
- Needing more money, which could dilute shareholders or limit its operations.
- Its sales and marketing may not succeed, and doctors and patients may not accept its products.
- Clinical trials may be delayed or fail, and regulators may not approve its candidates.
Income statement
Ascendis Pharma A/S lost money in fiscal 2025: a net loss of €228 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 446 | 445 | 392 | 560 | 616 |
| Debt incl. finance leases | 105 | 399 | 630 | 823 | 815 |
| Net debt (negative means net cash) | −341 | −46 | 238 | 264 | 199 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | 1.5x | — | — | — |
| Interest coverage | −115.5x | −18.3x | −10.3x | −4.3x | −1.7x |
| Current ratio | 8.0x | 5.4x | 0.9x | 1.2x | 1.0x |
| Quick ratio | 7.3x | 4.6x | 0.7x | 0.8x | 0.8x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 4 of 9 | 5 of 9 |
| Rule of 40 | 245.1% | — | — |
| Altman Z'' | — | — | — |
| Accruals ratio | −1.5% | −7.2% | −22.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 4 of 9 | 5 of 9 |
Compare
Put Ascendis Pharma A/S side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ascendis Pharma A/S | FY25 | 98.0% | −18.9% | — | — | — | 5 | |
| Repligen | FY25 | 16.4% | 7.5% | 12.7% | 2.4% | −1.7x | — | Compare |
| TG Therapeutics | FY25 | 87.3% | 20.0% | −4.0% | 29.0% | 0.4x | 4 | Compare |
| Harmony Biosciences | FY25 | 21.5% | 24.0% | 40.1% | 48.9% | — | 5 | Compare |
| BioCryst Pharmaceuticals | FY25 | 94.1% | 39.0% | 39.4% | — | −0.8x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 5 | 2 | 11 | 13 | 7 | 8 | 51 | 267 | 364 | 720 |
| Revenue growth | −43.3% | −66.8% | 591.6% | 26.4% | −48.0% | 11.9% | 557.9% | 421.2% | 36.3% | 98.0% |
| Gross profit | — | — | — | 13 | 7 | 4 | 39 | 222 | 319 | 625 |
| Research and development | 66 | 100 | 140 | 192 | 261 | 296 | 380 | 414 | 307 | 304 |
| Operating income | −73 | −112 | −155 | −227 | −331 | −452 | −562 | −456 | −279 | −136 |
| Net income | −68 | −124 | −130 | −218 | −419 | −384 | −583 | −481 | −378 | −228 |
| Diluted EPS (EUR) | −2.58 | −3.68 | −3.17 | −4.69 | −8.28 | −7.00 | −10.40 | −8.55 | −6.53 | −3.76 |
| Diluted shares (millions) | 27 | 34 | 41 | 46 | 51 | 55 | 56 | 56 | 58 | 61 |
| Cash flow | ||||||||||
| Cash from operations | −60 | −95 | −139 | −176 | −272 | −418 | −496 | −467 | −306 | 54 |
| Capital expenditure | 1 | 1 | 3 | 5 | 20 | 24 | 14 | 2 | — | — |
| Free cash flow | −61 | −96 | −141 | −181 | −291 | −441 | −510 | −470 | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 22 | 105 | 0 | 0 | 17 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 7 | 10 | 20 | 38 | 53 | 67 | 64 | 67 | 96 | 116 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 180 | 195 | 278 | 598 | 584 | 446 | 445 | 392 | 560 | 616 |
| Debt incl. finance leases | — | — | — | — | — | 105 | 399 | 630 | 823 | 815 |
| Total assets | 190 | 211 | 319 | 677 | 980 | 1,085 | 1,090 | 826 | 1,180 | 1,303 |
| Total liabilities | 14 | 24 | 39 | 80 | 141 | 201 | 826 | 971 | 1,285 | 1,465 |
| Shareholders' equity | 177 | 187 | 280 | 597 | 839 | 884 | 263 | −146 | −106 | −163 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | 100.0% | 100.0% | 54.7% | 76.3% | 83.4% | 87.8% | 86.8% |
| Operating margin | −1,583.2% | −7,290.3% | −1,462.6% | −1,695.1% | −4,755.1% | −5,808.6% | −1,097.8% | −170.8% | −76.7% | −18.9% |
| Net margin | −1,487.3% | −8,097.8% | −1,229.5% | −1,630.0% | −6,025.5% | −4,931.6% | −1,139.6% | −180.5% | −104.0% | −31.7% |
| Free cash flow margin | −1,321.1% | −6,277.1% | −1,336.8% | −1,354.0% | −4,191.1% | −5,674.4% | −997.0% | −176.1% | — | — |
| Rule of 40 (growth + FCF margin) | −1,364.4% | −6,343.9% | −745.3% | −1,327.6% | −4,239.1% | −5,662.5% | −439.0% | 245.1% | — | — |
| Return on capital | — | — | — | — | — | — | −116.8% | −232.2% | −176.0% | — |
| Return on equity | — | −68.1% | −55.7% | −49.7% | −58.4% | −44.5% | −101.7% | −818.4% | — | — |
| Return on assets | — | −61.8% | −49.1% | −43.8% | −50.6% | −37.2% | −53.6% | −50.3% | −37.7% | −18.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |